{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:16:23Z","timestamp":1770884183056,"version":"3.50.1"},"reference-count":14,"publisher":"BMJ","funder":[{"name":"Patty Blow Fund"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012643","name":"Ohio Lions Eye Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012643","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,6,7]]},"abstract":"<jats:p>A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3\u2009days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive <jats:italic>Staphylococcus aureus<\/jats:italic> endophthalmitis, bacteraemia and osteomyelitis of the foot. The patient had been started on the interleukin 17 (IL-17) inhibitor secukinumab for his treatment-resistant plaque psoriasis 4\u2009weeks prior to presentation. After treatment, his final vision was light perception and the foot infection resolved without sequelae. To our knowledge, this is the first reported case of both endogenous endophthalmitis and osteomyelitis associated with an IL-17 inhibitor.<\/jats:p>","DOI":"10.1136\/bcr-2017-219296","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T01:25:18Z","timestamp":1498785918000},"page":"bcr-2017-219296","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes"],"prefix":"10.1136","volume":"2017","author":[{"given":"Christine E","family":"Martinez","sequence":"first","affiliation":[{"name":"Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B","family":"Allen","sequence":"additional","affiliation":[{"name":"Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick H","family":"Davidorf","sequence":"additional","affiliation":[{"name":"Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen M","family":"Cebulla","sequence":"additional","affiliation":[{"name":"Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.1","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1167\/iovs.15-17488","article-title":"Blood\u2013retinal barrier ompromise and ndogenous Staphylococcus aureus endophthalmitis","volume":"56","author":"Coburn","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181ecccf0"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2014.06.002"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.4","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/261310","article-title":"An eleven-year retrospective study of endogenous bacterial endophthalmitis","volume":"2015","author":"Nishida","year":"2015","journal-title":"J Ophthalmol"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.5","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ophtha.2014.02.001","article-title":"Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review","volume":"121","author":"Gentile","year":"2014","journal-title":"Ophthalmology"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.6","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.N.01350"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.04.006"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/CCID.S81160","article-title":"Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab","volume":"9","author":"Malakouti","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.10","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-20-11-684"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/eye.2015.200","article-title":"Staphylococcal endogenous endophthalmitis in association with pyogenic vertebral osteomyelitis","volume":"30","author":"Steeples","year":"2016","journal-title":"Eye"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/09273948.2012.676702","article-title":"Bilateral endogenous endophthalmitis associated with methicillin sensitive Staphylococcus aureus (MSSA) related tenosynovitis: case report","volume":"20","author":"Agrawal","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2025082804312171000_2017.jun29_2.bcr-2017-219296.14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-219296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:31:30Z","timestamp":1756380690000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-219296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":14,"alternative-id":["10.1136\/bcr-2017-219296"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-219296","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]}}}